-+ 0.00%
-+ 0.00%
-+ 0.00%
Betta Pharmaceuticals announced that the marketing license application for ensartinib hydrochloride capsules declared by Xdiscovery, a holding subsidiary of the company, was approved by the European Commission. The marketing license number EU/1/26/2078 is used for the treatment of adult patients with advanced anaplastic lymphoma kinase positive advanced non-small cell lung cancer. Ensatinib became the first domestically produced ALK inhibitor approved for marketing in China, the US, and the European Union.
Share
Listen to the news
Betta Pharmaceuticals announced that the marketing license application for ensartinib hydrochloride capsules declared by Xdiscovery, a holding subsidiary of the company, was approved by the European Commission. The marketing license number EU/1/26/2078 is used for the treatment of adult patients with advanced anaplastic lymphoma kinase positive advanced non-small cell lung cancer. Ensatinib became the first domestically produced ALK inhibitor approved for marketing in China, the US, and the European Union.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending